Blood test may predict kidney cancer drug response
NCT ID NCT03185039
First seen Mar 27, 2026 · Last updated May 13, 2026 · Updated 6 times
Summary
This study is looking at two substances in the blood, called MMP2 and MMP9, to see if they can help predict how well certain drugs work in people with kidney cancer that has spread. The researchers will measure these markers in 50 patients and track their cancer progression. The goal is to better understand which patients might benefit from anti-angiogenic therapy, not to test a new treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut Paoli Calmettes
Marseille, 13009, France
Conditions
Explore the condition pages connected to this study.